OKYO – okyo pharma limited - ordinary shares (US:NASDAQ)
Stock Stats
News
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting [Yahoo! Finance]
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
OKYO Pharma (NASDAQ:OKYO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
OKYO Pharma Announces Successful Type C Meeting with the FDA
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
Form F-3 OKYO Pharma Ltd
Form 6-K OKYO Pharma Ltd For: Jan 30
Form 6-K OKYO Pharma Ltd For: Jan 30
Form 6-K OKYO Pharma Ltd For: Jan 28
Form 6-K OKYO Pharma Ltd For: Jan 23
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.